Orasis Pharmaceuticals Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.orasis-pharma.com
Clinical Trials
6
Active:0
Completed:6
Trial Phases
2 Phases
Phase 2:3
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (50.0%)Phase 3
3 (50.0%)An Evaluation of the Safety of CSF-1 in Presbyopic Subjects
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Orasis Pharmaceuticals Ltd.
- Target Recruit Count
- 178
- Registration Number
- NCT05393895
- Locations
- 🇺🇸
Orasis Investigative Site, Cedar Park, Texas, United States
An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Orasis Pharmaceuticals Ltd.
- Target Recruit Count
- 304
- Registration Number
- NCT04599972
- Locations
- 🇺🇸
Orasis Investigative Site, Lynchburg, Virginia, United States
An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1)
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Orasis Pharmaceuticals Ltd.
- Target Recruit Count
- 309
- Registration Number
- NCT04599933
- Locations
- 🇺🇸
Orasis Investigative Site, El Paso, Texas, United States
A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia
Phase 2
Completed
- Conditions
- Presbyopia
- Interventions
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Orasis Pharmaceuticals Ltd.
- Target Recruit Count
- 166
- Registration Number
- NCT03885011
- Locations
- 🇺🇸
Orasis Investigative Site, Draper, Utah, United States
Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects
Phase 2
Completed
- Conditions
- Presbyopia
- Interventions
- Drug: PresbiDrops (CSF-1)Drug: Placebo
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Orasis Pharmaceuticals Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT02965664
- Locations
- 🇮🇱
Ophthalmology Department, Western Galilee Medical Center, Nahariya, Israel
🇮🇱The Department of Ophthalmology, Kaplan Medical Center, Rehovot, Israel
- Prev
- 1
- 2
- Next
News
No news found